Erythropoietin expression promoter
The present invention provides an erythropoietin expression-enhancing agent that can cancel the suppression of erythropoietin production or promote erythropoietin production, and a therapeutic or preventive drug for anemia, a liver function-improving agent, an ischemic injury-improving agent, a renal protective agent, and an insulin secretagogue comprising the erythropoietin expression-enhancing agent. The erythropoietin expression-enhancing agent of the present invention comprises one or more compounds selected from the group consisting of compounds represented by the following general formulas (I), (II), and (III) and pharmaceutically acceptable salts thereof when R 3 is OH.
1. A compound represented by the following formula (I-1′), (I-1″), (I-2), (I-2″), (I-2′″), (I-3), (I-3′), (II-2), (III), or (IV-1) or a pharmaceutically acceptable salt thereof:
wherein A represents indole, and positions 3 and 5 of the indole are each substituted by an acetic acid group and R 7 O, R 7 represents an alkyl group having 1 to 5 carbon atoms or a benzyl group, wherein when R 7 represents an alkyl group, R 3 represents any one group selected from OR 4 , NHR 4 and NR 4 R 5 , and R 4 and R 5 are the same or different and each represents an unsubstituted alkyl group having 1 to 4 carbon atoms, and wherein when R 7 represents a benzyl group, the benzene ring of the benzyl group is substituted by one or more alkyl groups having 1 to 3 carbon atoms or alkoxyl groups having 1 to 3 carbon atoms, R 3 represents any one group selected from OH, OR 4 , NHR 4 , and NR 4 R 5 , and R 4 and R 5 are the same or different and each represents a substituted or unsubstituted alkyl group having 1 to 4 carbon atoms,
2. The compound according to claim 1 , which is represented by the following formula (III-1):
or a pharmaceutically acceptable salt thereof.